NEWS
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
Kronos Bio has announced the selection of KB-7898, a p300 KAT inhibitor, as its first development candidate for autoimmune diseases, specifically targeting Sjögren’s disease. This candidate stems from Kronos Bio's proprietary discovery engine, which decodes complex transcription factor regulatory networks.
Preclinical data for KB-7898 will be presented at ACR Convergence 2024. The data indicate that p300 KAT inhibition can reduce antibody production in B cells and cytokine production in T cells. Kronos Bio plans to initiate IND-enabling studies of KB-7898 in Q4 2024. The company also intends to explore the candidate's utility in other autoimmune diseases in the future.
The preclinical studies showed promising results, including selective downregulation of cytokines and significant decreases in inflammation in animal models. The presentation will be available on Kronos Bio's website on November 14, 2024, and the abstract is available on the American College of Rheumatology’s website.
Preclinical data for KB-7898 will be presented at ACR Convergence 2024. The data indicate that p300 KAT inhibition can reduce antibody production in B cells and cytokine production in T cells. Kronos Bio plans to initiate IND-enabling studies of KB-7898 in Q4 2024. The company also intends to explore the candidate's utility in other autoimmune diseases in the future.
The preclinical studies showed promising results, including selective downregulation of cytokines and significant decreases in inflammation in animal models. The presentation will be available on Kronos Bio's website on November 14, 2024, and the abstract is available on the American College of Rheumatology’s website.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2554Followers
107Following
28KVisitors
Follow